Click here to view the September 2023 edition of The Meeting Place!

• Eva-Lotta Allan’s excellent track record of corporate, business development and operational experience strengthens industry-leading Board and Executive Leadership team • Maxion’s lead KnotBody® programme is progressing rapidly towards preclinical development with a first-in-class and best-in-class potential Cambridge, UK – 21 September 2023 – Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its…

Unlock a 25% discount today on all OGM services with Source Genomics, limited time only. OGM is introducing a new dimension to genomic analysis, taking a high-resolution snapshot of genome structure in its entirety, including structural variants and large-scale re-arrangements. Researchers from all avenues of the genomic medicine field can anticipate OGM to play a key role in diagnosing genetic diseases more accurately, accelerating drug discovery by revealing target genes and pathways and uncovering novel genetic variations linked to complex conditions. While many industry and academic…

Anglia Ruskin University has been shortlisted for the University of the Year award in this year’s Times Higher Education (THE) Awards, widely known as the Oscars of the UK university sector. They are also shortlisted for the Outstanding Contribution to the Local Community award (for the creation of ARU Peterborough) and Outstanding Contribution to Equality, Diversity and Inclusion award (for our SHoKE project).  Visit THE University of the Year shortlist - ARU for more information and a short film showcasing their achievements can be viewed here: https://youtu.be/9ct3syztzsw.

In their latest podcast, Optimum Stategic Communications dicuss the hot areas for investment in the shifting biotech market - including antibody-drug conjugates, smart radiotherapies, mRNA and immune-oncology.  Listen now!

Webinar will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, is hosting a webinar entitled “Uncooperative Drugs in In Vitro Transporter Research: Practical Approaches to Address Instability and Nonspecific Binding Challenges” at 11 am ET on September 20. “In vitro drug transporter data are critical for understanding a compound’s drug-drug interaction potential. But if the compound being investigated is unstable, sticky…

Funds to support further development and commercialization of the Company’s INDUCE-seq DNA break mapping technology Platform technology provides in situ off-target measurement in clinically relevant cells to accelerate the progression of cell and gene therapy programs New investors include Illumina Ventures, Mérieux Equity Partners, and HERAN Partners Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that…

Recognising that research and development and production of medicines requires a significant amount of energy, AstraZeneca recently shared an article on 'Powering emissions reductions with clean heat and renewable energy' explaining how they are working toward net zero goals with innovative partnerships.  Read the full article

"The addition of the 1.25 millionth structure to the CSD is a great achievement for the community. Being the world’s largest database of small-molecule organic and metal-organic crystal structure data, the CSD is used in over 70 countries by scientists and crystallographers working both in academia and in pharmaceutical companies. Each of the structures deposited by scientists from around the globe is curated by our expert scientific editors prior to entry in the database. It represents a fundamental platform to access structural data, to understand how molecules behave and interact in three…

After five years of leading LifeArc, Dr. Melanie Lee has informed the Board of her decision to step down as Chief Executive Officer.  Read the full press release.